FDA approves GSK hepatitis B drug; EQT to acquire Qiagen for $10.8 billion
The U.S. Food and Drug Administration has granted approval to GlaxoSmithKline's new hepatitis B therapy, marking a regulatory milestone for the company.
Private-equity firm EQT announced a definitive agreement to purchase molecular-testing company Qiagen for $10.8 billion, expanding its life-science portfolio.
The approval adds a new treatment option for hepatitis B patients, while the acquisition signals continued consolidation in the diagnostics sector.
Both developments are likely to influence market dynamics, with investors watching GSK's product pipeline and EQT's strategic expansion.
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Recon: FDA approves GSK hepatitis B drug; EQT to buy molecular testing firm Qiagen for $10.8B”
read at raps ↗
comments(0)
5-min edit window · permanent after that